Donor-specific antibodies are associated with antibody-mediated rejection, acute cellular rejection, bronchiolitis obliterans syndrome, and cystic fibrosis after lung transplantation

Lobo, Leonard J.; Aris, Robert M.; Schmitz, John L.; Neuringer, Isabel P.

doi:10.1016/j.healun.2012.10.007

Cited by 144 publications

(148 citation statements)

References 50 publications

Supporting

Mentioning

133

Contrasting

Order By: Relevance

“…In a large study of renal allografts, Lachmann et al showed that DSA detected post-transplant using Luminex single-antigen bead assays were associated with significantly reduced graft survival, 10 whereas we previously found de novo DSA after cardiac transplantation to be an independent predictor of poor patient survival. 12 As with other studies 12,18,19 the majority of DSA detected in this study were directed against HLA Class II antigens, particularly HLA-DQ. Of the 28 patients with Class II directed DSA, 25 (89%) were found to be directed against donor HLA-DQ specificities.…”

Section: Discussionsupporting

confidence: 87%

De novo donor HLA-specific antibodies predict development of bronchiolitis obliterans syndrome after lung transplantation

Safavi

Robinson

Soresi

et al. 2014

The Journal of Heart and Lung Transplantation

113

104

View full text Add to dashboard Cite

(2014) De novo donor HLA-specific antibodies predict development of bronchiolitis obliterans syndrome after lung transplantation. The Journal of Heart and Lung Transplantation, 33 (12). pp. 1273 -1281 . ISSN 1053 -2498 This version is available from Sussex Research Online: http://sro.sussex.ac.uk/56766/ This document is made available in accordance with publisher policies and may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher's version. Please see the URL above for details on accessing the published version. Copyright and reuse:Sussex Research Online is a digital repository of the research output of the University.Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable, the material made available in SRO has been checked for eligibility before being made available.Copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way. There was a significant reduction in patient survival associated with de novo DSA (HR ¼ 1.886, p ¼ 0.047). In multivariable analyses, de novo DSA was an independent predictor for development of all stages of BOS as well as an independent predictor of poor patient survival. CONCLUSIONS: De novo DSA is a major risk factor for progression to BOS and shorter patient survival. Treatments to remove antibodies or limit antibody-mediated damage could be considered when DSA are first detected. However, a randomized, controlled trial of treatment options would enable a clearer understanding of the benefits, if any, of antibody-removal therapies.

show abstract

Section: Discussionsupporting

confidence: 87%

De novo donor HLA-specific antibodies predict development of bronchiolitis obliterans syndrome after lung transplantation

Safavi

Robinson

Soresi

et al. 2014

The Journal of Heart and Lung Transplantation

113

104

View full text Add to dashboard Cite

show abstract

“…The frequency of AMR (10.5%) in our cohort is higher than the frequency reported in a similar data set by Witt et al (4.3%) (16) but lower than the incidence reported by Lobo et al (27%) (13). Furthermore, Witt et al (16) described a longer median delay for AMR appearance (258 days) but a similar proportion of patients with AMR in the first 45 days (7 of 21 patients).…”

Section: Discussioncontrasting

confidence: 74%

Antibody-Mediated Rejection in Lung Transplantation: Clinical Outcomes and Donor-Specific Antibody Characteristics

Roux

Lan

Holifanjaniaina

et al. 2016

American Journal of Transplantation

119

View full text Add to dashboard Cite

show abstract

“…Moreover, antibody-mediated rejection (AMR) is now recognized as a cause of allograft loss in all solid organ transplants despite significant differences in incidence and outcome (6)(7)(8)(9)(10)(11). Historically, it has been recognized that the liver is relatively resistant to the pathologic effects of DSA compared to other solid organs (12)(13)(14)(15).…”

Section: Introductionmentioning

confidence: 99%

Impact of IgG3 Subclass and C1q-Fixing Donor-Specific HLA Alloantibodies on Rejection and Survival in Liver Transplantation

O’Leary

Kaneku

Banuelos

et al. 2015

American Journal of Transplantation

132

128

View full text Add to dashboard Cite

Donor-specific antibodies are associated with antibody-mediated rejection, acute cellular rejection, bronchiolitis obliterans syndrome, and cystic fibrosis after lung transplantation

Cited by 144 publications

References 50 publications

De novo donor HLA-specific antibodies predict development of bronchiolitis obliterans syndrome after lung transplantation

De novo donor HLA-specific antibodies predict development of bronchiolitis obliterans syndrome after lung transplantation

Antibody-Mediated Rejection in Lung Transplantation: Clinical Outcomes and Donor-Specific Antibody Characteristics

Impact of IgG3 Subclass and C1q-Fixing Donor-Specific HLA Alloantibodies on Rejection and Survival in Liver Transplantation

Contact Info

Product

Resources

About